Thrombophilia testing - indications & interpretation
thrombophilia testing · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Thrombophilia screening is of limited value in most VTE and rarely changes management; it should be targeted, correctly timed, and interpreted with awareness of how acute thrombosis and anticoagulants distort results.
Red flags
- Thrombosis at unusual sites (cerebral, splanchnic, portal)
- Recurrent VTE despite anticoagulation
- Arterial and venous thrombosis together
- Recurrent pregnancy loss with thrombosis
- Warfarin-induced skin necrosis (protein C deficiency)
Assessment
Differential diagnosis
- Inherited: factor V Leiden, prothrombin G20210A, protein C/S/antithrombin deficiency
- Acquired: antiphospholipid syndrome
- Myeloproliferative neoplasm (JAK2)
- Paroxysmal nocturnal haemoglobinuria
- Malignancy-associated hypercoagulability
Investigations
- Antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein-I
- Factor V Leiden and prothrombin G20210A gene tests
- Protein C, protein S and antithrombin activity
- JAK2 V617F if splanchnic/unusual-site thrombosis
- PNH flow cytometry in appropriate settings
- FBC and film
Management
- Decide whether testing will change management - usually it does not after a first provoked VTE
- Do not test routinely in provoked VTE or where lifelong anticoagulation is already indicated
- Consider antiphospholipid testing in unprovoked VTE, arterial events, recurrent pregnancy loss or unusual sites
- Consider heritable thrombophilia testing only where a positive result would alter management (e.g. duration, family counselling)
- Time tests correctly: not during acute thrombosis, and account for anticoagulant interference
- Measure protein C/S and antithrombin away from acute events and off anticoagulation (or interpret cautiously)
- Confirm antiphospholipid antibodies on two occasions at least 12 weeks apart
- Interpret in clinical context and counsel on absolute (not just relative) risk
- Involve haematology for complex or discrepant results
- Use results to guide anticoagulation duration and family counselling, not to over-treat
Drugs & doses
No drug therapy for testing itself; results may influence anticoagulant choice and duration (see VTE management)
Disposition
Outpatient / haematology-guided; counsel patients and relevant family members; integrate into anticoagulation decisions.
Complications & pitfalls
- Misleading results during acute thrombosis or anticoagulation
- Unnecessary anxiety and over-anticoagulation
- False reassurance from a negative screen
- Missed antiphospholipid syndrome if not confirmed twice
- Inappropriate testing of asymptomatic relatives
Exam pearls
- Heritable thrombophilia rarely changes management after a first VTE
- Antithrombin, protein C and protein S fall during acute clot and on anticoagulants - time testing carefully
- DOACs cause false-positive lupus anticoagulant results
- Antiphospholipid antibodies must be persistent (repeat at 12 weeks)
- Unusual-site thrombosis warrants JAK2 and PNH consideration
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.